Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain

被引:0
作者
Ruiz, Sara Jimeno [1 ,2 ,3 ]
Pelaez, Adrian [3 ,4 ,5 ]
Gomez, Angeles Calle [1 ,2 ,3 ]
Garcia-Lomas, Mercedes Villarreal [3 ,6 ]
Martinez, Silvina Natalini [1 ,2 ,3 ]
机构
[1] Hosp HM Puerta Sur, HM Hosp, Dept Pediat, Madrid 28938, Spain
[2] HM Hosp, Unidad Vacunas, Madrid 28938, Spain
[3] Univ Camilo Jose Cela, HM Hosp, Fac Ciencias Salud, Madrid 28692, Spain
[4] Fdn Invest HM Hosp, Dept Unidad Anal Datos, Madrid 28938, Spain
[5] Inst Salud Carlos III ISCIII, Ctr Invest Red Enfermedades Resp CIBERES, Madrid 28029, Spain
[6] Hosp HM, Hosp HM Torrelodones, Dept Med Interna, Madrid 28250, Spain
关键词
respiratory syncytial virus; respiratory viruses; elder population; hospitalization; ICU admission; mortality; INFECTIONS;
D O I
10.3390/geriatrics9060145
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Objectives: Respiratory illnesses frequently lead to hospitalization in adults aged 60 and older, especially due to respiratory viral infectious (RVI). This study investigates hospitalization patterns and characteristics of RVI at HM Hospitals from October 2023 to March 2024; Methods: We retrospectively explored hospitalizations of patients aged 60 years and older with RVIs, gathering data on demographics, clinical profiles, comorbidities, and treatments. Outcomes included hospitalization, ICU admissions, and mortality, and independent factors associated with outcomes were identified using a multi-state model; Results: From October 2023 to March 2024, from a total of 3258 hospitalizations, 1933 (59.3%) were identified as positive for RVIs. Overall, SARS-CoV-2 was the most prevalent (52.6%), followed by influenza (32.7%), and RSV (11.8%). Most RVI involved single infections (88.2%). Hospitalization rates increased with age for SARS-CoV-2 (333.4 [95% CI: 295.0-375.2] to 651.6 [95% CI: 532.1-788.4]), influenza (169.8 [95% CI: 142.6-200.7] to 518.6 [95% CI: 412.1-643.1]), and RSV (69.2 [95% CI: 52.2-90.0] to 246.0 [95% CI: 173.8-337.5]), with SARS-CoV-2 showing the highest rate, followed by influenza and RSV. In the multi-state model, RSV infection significantly increased ICU admission risk (HR: 2.1, 95%, p = 0.037). Age on admission (HR: 1.1, 95%, p < 0.001) and Charlson score (HR: 1.4, 95%, p = 0.001) were associated with transitioning from admission to death. ICU to death risks included age at admission (HR: 1.7, 95%, p < 0.001); Conclusions: RVI in adults 60 years and older are associated with high hospitalization and mortality rates, primarily driven by influenza and SARS-CoV-2, followed by RSV. Age and comorbidities significantly impact disease severity, emphasizing the need for targeted prevention and management strategies for RSV in this vulnerable population.
引用
收藏
页数:14
相关论文
共 35 条
  • [11] Leonardo R.O., Infecciones por VRS y gripe en adultos: Más en común de lo que parece, Enfermedades Infecc. Y Microbiol. Clín, 42, pp. 59-61, (2024)
  • [12] Martin G.L., Garcia A.F., Iribarren A.D., de Cabo M.M., Segarra O.M., Vegas-Serrano A., Infección por virus respiratorio sincitial en adultos: Diferencias con la gripe, Enferm. Infecc. Microbiol. Clin, 42, pp. 62-68, (2024)
  • [13] Branche A.R., Saiman L., Walsh E.E., Falsey A.R., Sieling W.D., Greendyke W., Peterson D.R., Vargas C.Y., Phillips M., Finelli L., Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020, Clin. Infect. Dis, 74, pp. 1004-1011, (2022)
  • [14] Shi T., Vennard S., Jasiewicz F., Brogden R., Nair H., Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: A systematic review and meta-analysis, J. Infect. Dis, 226, pp. 17-21, (2022)
  • [15] Nam H.H., Ison M.G., Respiratory syncytial virus infection in adults, BMJ, 366, (2019)
  • [16] Papi A., Ison M.G., Langley J.M., Lee D., Leroux-Roels I., Martinon-Torres F., Schwarz T.F., van Zyl-Smit R.N., Campora L., Dezutter N., Et al., Respiratory syncytial virus prefusion F protein vaccine in older adults, N. Engl. J. Med, 388, pp. 595-608, (2023)
  • [17] Villar-Alvarez F., de la Rosa-Carrillo D., Farinas-Guerrero F., Vacunación en el paciente respiratorio adulto,¿ bailamos?, Vacunas, 24, pp. 161-163, (2023)
  • [18] Delgado-Sanz C., Mazagatos C., Diaz R., Galindo S., Monge S., Larrauri A., Informe de Situación Sobre la Circulación del Virus. Respiratorio Sincitial al Inicio de la Temporada 2022–2023, (2022)
  • [19] Reina J., de Herrero E.G., Situación actual y perspectivas de futuro de las vacunas frente al virus respiratorio sincitial, Vacunas, 24, pp. 150-157, (2023)
  • [20] Graham B.S., The journey to RSV vaccines—Heralding an era of structure-based design, N. Engl. J. Med, 388, pp. 579-581, (2023)